Table 2.
Summary of clinical trials scheduled for curcumin assessment as an element of anticancer strategies (according to ClinicalTrials.gov.).
| Cancer | Inclusion Criteria | Intervention | Outcome Measures | Phase | Clinical Trial Number |
|---|---|---|---|---|---|
| Endometrial carcinoma | Recurrent with no life-threatening metastases | Curcuphyt (curcumin analogue), standard chemotherapy | Anti-inflammatory effect | Recruiting, 2 | NCT02017353 |
| Prostate cancer | Life expectancy > 5 years | Curcumin, curcumin analogue BCM95, radiotherapy | Radiosensitizing and radioprotective effect | Recruiting, data not shown | NCT01917890 |
| Breast cancer | Completed chemotherapy | Curcumin, radiotherapy | Level of NF-κβ DNA binding | Not yet recruiting, 2 | NCT01740323 |
| Colorectal cancer | Familial adenomatous polyposis, stage 0 | Curcumin | Number and size of polyps, side effect of curcumin, involved pathways | Recruiting | NCT00641147 |
| Lymphocytic lymphoma Lymphocytic leukemia | Stage 0,1,2 | Curcumin, vitamin D | Overall survival response, Overall survival rates, progression free survival | Not yet recruiting, 2 | NCT02100423 |
| Prostate cancer | Metastatic cancer, castration resistant | Curcumin, Taxotere | Time to progression, tumor response by RECIST criteria | Recruiting, 2 | NCT02095717 |
| Colorectal cancer | Metastatic cancer | Curcumin, chemotherapy | Neuropathic side-effect, disease response, disease survival, level of biomarkers | Recruiting, 1, 2 | NCT01490996 |
| Colon cancer | First diagnosed primary tumor without any treatment | Curcumin, curcumin conjugated with plant exosomes (Exo-cur) | Efficiency of plant exosomes in delivering curcumin to normal colon tissue and colon tumor | Recruiting, 1 | NCT01294072 |
| Intestinal adenomas | Familial adenomatous polyposis with an intact colon or with surgery | Curcumin (Calcumin) | Regression of intestinal adenomas | Recruiting, data not shown | NCT00927485 |
| Solid tumors | Advanced or metastatic cancer, life expectancy > 3 months | Liposomeal curcumin intravenous | Safety, tolerability and pharmacokinetic of liposomeal curcumin, tumor response by RECIST criteria | Recruiting, 1 | NCT02138955 |
| Breast cancer | Atypical ductal breast hyperplasia BRCA1 gene mutation BRCA2 gene mutation ductal breast carcinoma in situ lobular breast carcinoma in situ | Nanoemulsion formulation of curcumin | Adherence, tolerability and safety of curcumin, anti-inflammatory changes | Recruiting, pilot study | NCT01975363 |
| Colorectal cancer | Metastatic cancer | Curcumin, irinotecan | Safety, pharmacokinetics and effectiveness of irinotecan in combination with curcumin | Recruiting, 1 | NCT01859858 |
| Colorectal cancer | Familial adenomatous polyposis, stage 0 | Phospholipid curcumin, anthocyanin extract | Markers, apoptosis, cell proliferation | Recruiting, 2 | NCT01948661 |
| Prostate cancer | Stage T1–T3 | Curcumin, curcumin analogue BCM-95CG | Time of recurrence-free survival | Recruiting, 2 | NCT02064673 |